ReviewEuropean respiratory review : an official journal of the European Respiratory Society2014
New clinical research strategies in thoracic oncology: clinical trial design, adaptive, basket and umbrella trials, new end-points and new evaluations of response.
Review in European respiratory review : an official journal of the European Respiratory Society, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed.
- Combined integrated protocol/basket trial design for a first-in-human trial.Orphanet journal of rare diseases · 2016Trial
- The Growth Modulation Index (GMI) as an Efficacy Outcome in Cancer Clinical Trials: A Scoping Review with Suggested Reporting Guidelines.Current oncology reports · 2025Article
- Article
- Effectiveness and safety of transarterial chemoembolization combined with PD-1 inhibitors and lenvatinib for unresectable intrahepatic cholangiocarcinoma.European radiology experimental · 2025Article
- MulitDeepsurv: survival analysis of gastric cancer based on deep learning multimodal fusion models.Biomedical optics express · 2025Article
- Reporting and communication of sample size calculations in adaptive clinical trials: a review of trial protocols and grant applications.BMC medical research methodology · 2024Review
- Review
- Transarterial chemoembolization with molecular targeted therapies plus camrelizumab for recurrent hepatocellular carcinoma.BMC cancer · 2024Article
- Advancing non-small cell lung cancer treatment: the power of combination immunotherapies.Frontiers in immunology · 2024Review
- Inflammation across tissues: can shared cell biology help design smarter trials?Nature reviews. Rheumatology · 2023Review
- Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001).Signal transduction and targeted therapy · 2023Article
- How to optimize the incorporation of immunotherapy in trials for oligometastatic non-small cell lung cancer: a narrative review.Translational lung cancer research · 2021Review
- Immunotherapy in malignant pleural mesothelioma: a review of literature data.Translational lung cancer research · 2021Review
- Article
- Design and Endpoints of Clinical Trials, Current and Future.Digestive diseases and sciences · 2019Review
- New clinical trial designs in the era of precision medicine.Molecular oncology · 2019Review
- Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology.Journal of the National Cancer Institute · 2019Review
- Landscape of Actionable Genetic Alterations Profiled from 1,071 Tumor Samples in Korean Cancer Patients.Cancer research and treatment · 2019Article
- Challenges and shifting paradigms in clinical trials in oncology: the case for immunological and targeted therapies.Ecancermedicalscience · 2019Review
- Master protocol trials in oncology: Review and new trial designs.Contemporary clinical trials communications · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the genomics era, our main goal should be to identify large and meaningful differences in small, molecularly selected groups of patients. Classical phase I, II and III models for drug development require large resources, limiting the number of experimental agents that can be tested and making the evaluation of targeted agents inefficient. There is an urgent need to streamline the development of new compounds, with the aim of identifying "trials designed to learn", which could lead to subsequent "trials designed to conclude". Basket trials are often viewed as parallel phase II trials within the same entity, designed on the basis of a common denominator, which can be a molecular alteration(s). Most basket trials are histology-independent and aberration-specific clinical trials. Umbrella trials are built on a centrally performed molecular portrait and molecularly selected cohorts with matched drugs, and can include patients' randomisation and strategy validation. Beyond new designs, new end-points and new evaluation techniques are also warranted to finally achieve methodology and clinical improvements, in particular within immunotherapy trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.